Ribo Newsroom
-
Ribo's International R&D Center Ribocure Closes USD 33 Million Equity Financing to Accelerate Innovative siRNA Drug DevelopmentThe International R&D Center Ribocure closes USD 33 Million equity financing round.July 16, 2025 -
Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaRibo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaFebruary 26, 2025 -
First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimFirst Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimJanuary 10, 2025 -
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeuticsSeptember 24, 2024 -
Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase I Clinical Data At ESC Congress 2024August 31, 2024 -
Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNAInnovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.April 8, 2024